Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Head & Neck 1 Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 160 venetoclax 149 Cytarabine 123 Rituximab 94 fludarabine 76 Cyclophosphamide 70 Imatinib Mesylate 59 nilotinib 55 ibrutinib 54 Dasatinib 48 obinutuzumab 47 Bendamustine Hydrochloride 43 Decitabine 39 Daunorubicin 38 idelalisib 31 acalabrutinib 31 Dexamethasone 29 Chlorambucil 29 Idarubicin 26 gilteritinib 24 Lenalidomide 23 bosutinib 21 asciminib 21 ofatumumab 20 blinatumomab 19 pirtobrutinib 18 fludarabine phosphate 18 Vincristine 18 zanubrutinib 16 ublituximab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × ficlatuzumab × Other hematologic neoplasm × Clear all

NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡